Thyroid Cancer Therapeutics Market, By Type (Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer (MTC), Anaplastic Thyroid Cancer, Hurthle Cell Cancer), By Therapy (Drugs, Radiation Therapy, Other Therapies), By Region (North America, Europe, Asia Pacific, Middle East & Africa, and South America) – Market Size & Forecasting To 2028

Thyroid cancer is a type of cancer that develops in the thyroid gland and can spread to other parts of the body. The thyroid gland produces hormones that regulate blood pressure, heart rate, energy metabolism, and body temperature. There are four main types of thyroid cancer, classified based on the types of cells where cancer begins papillary, follicular, medullary and anaplastic thyroid cancer. Papillary carcinomas are slow-growing, differentiated cancers that develop from follicular cells and can develop in one or both lobes of the thyroid gland. This type of cancer may spread to nearby lymph nodes in the neck, but it is generally treatable with a good prognosis. Follicular carcinoma is the second most common type of thyroid cancer, and accounts for approximately one out of 10 cases. It is found more frequently in countries with an inadequate dietary intake of iodine. Follicular carcinoma is also a differentiated form of thyroid cancer. In most cases, it is associated with a good prognosis, although it is somewhat more aggressive than papillary cancer. Follicular carcinomas do not usually spread to nearby lymph nodes, but they are more likely than papillary cancers to spread to other organs, like the lungs or the bones. Hürthle cell carcinoma, also known as oxyphil cell carcinoma, is a subtype of follicular carcinoma, and accounts for approximately 3 percent of all thyroid cancers. The thyroid gland is a butterfly-shaped gland that wraps around the front of the windpipe. The thyroid gland is a part of the endocrine system, that produces and controls the hormones in the body. Medullary thyroid carcinoma develops from C cells in the thyroid gland, and is more aggressive and less differentiated than papillary or follicular cancers. Approximately 4 percent of all thyroid cancers will be of the medullary subtype. These cancers are more likely to spread to lymph nodes and other organs, compared with the more differentiated thyroid cancers. They also frequently release high levels calcitonin and carcinoembryonic antigen (CEA), which can be detected by blood tests. Anaplastic carcinoma is the most undifferentiated type of thyroid cancer, meaning that it looks the least like normal cells of the thyroid gland. As a result, it is a very aggressive form of cancer that quickly spreads to other parts of the neck and body. It occurs in approximately 2 percent of thyroid cancer cases. Papillary thyroid cancer is the most common type of thyroid cancer, accounting for about 80% of all cases.

Thyroid cancer typically doesn't cause any signs or symptoms early in the disease. As thyroid cancer grows, it may cause a lump (nodule) that can be felt through the skin on the neck, difficulties in swallowing, pain in neck and throat, and swollen lymph nodes in the neck. As per the American Society of Clinical Oncology in 2019, approximately 14,260 men and 37,810 women in the United States were diagnosed with thyroid cancer. It is the most common cancer in women between 20 to 34 years of age and women are more likely to develop thyroid cancer than men. About 2% of cases occur in children and teens. In addition, rise in thyroid cancer can be attributed to family history of goitre, exposure to radiation and some hereditary syndromes. Thyroid cancer is cancer that develops from the tissues of the thyroid gland in which cells grow abnormally and have the potential to spread to other parts of the body. Thyroid cancer therapeutics market is segmented by type, therapy, and geography. Thyroid cancer is divided into papillary and follicular thyroid cancer. These cancer types are called as differentiated cancer since papillary and follicular thyroid cancer differ in their biological behaviour and may require distinct therapeutic approach. Thyroid cancer is commonly diagnosed between the ages of 30 and 60, although it can occur at any age. Increasing size of nodule in patient is the primary symptom of differentiated thyroid cancer. Cough, dyspnea and dysphagia are the symptoms of advanced stage. Treatment includes surgery, followed by medication treatment. Treatment on thyroid related problems depends on type and stage of overall health.

Some of the impact factors:

  • Rising cases of thyroid cancer worldwide, increasing government funds, and growing awareness regarding thyroid cancer treatment options are the key driving factors in thyroid cancer therapeutics market
  • Increasing awareness about the cancer disease, raising government funds and reimbursement policies are the key factors which are expected to propel the overall differentiated thyroid cancer therapeutic market
  • increasing geriatric population as this disease is more prominent in elderly patients

What does this report provide?

Thyroid Cancer Therapeutics market report provides a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Market Segmentation:

By Type:

  • Papillary Thyroid Cancer
  • Follicular Thyroid Cancer
  • Medullary Thyroid Cancer (MTC)
  • Anaplastic Thyroid Cancer
  • Hurthle Cell Cancer

By Therapy:

  • Drugs
  • Radiation Therapy
  • Other Therapies

By Region:

North America Thyroid Cancer Therapeutics Market

  • North America, by Country
    • US
    • Canada
    • Mexico
  • North America, by Type
  • North America, by Therapy

Europe Thyroid Cancer Therapeutics Market

  • Europe, by Country
    • Germany
    • Russia
    • UK
    • France
    • Italy
    • Spain
    • The Netherlands
    • Rest of Europe 
  • Europe, by Type
  • Europe, by Therapy

Asia Pacific Thyroid Cancer Therapeutics Market

  • Asia Pacific, by Country
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Indonesia
    • Rest of Asia Pacific 
  • Asia Pacific, by Type
  • Asia Pacific, by Therapy

Middle East & Africa Thyroid Cancer Therapeutics Market

  • Middle East & Africa, by Country 
    • UAE
    • Saudi Arabia
    • Qatar
    • South Africa
    • Rest of Middle East & Africa
  • Middle East & Africa, by Type
  • Middle East & Africa, by Therapy

South America Thyroid Cancer Therapeutics Market

  • South America, by Country 
    • Brazil
    • Argentina
    • Colombia
    • Rest of South America
  • South America, by Type
  • South America, by Therapy

Major Companies: Sanofi (Genzyme Corporation), Exelixis, Inc, Medtronic Plc, Eisai Co., Ltd, Bayer AG, AbbVie Inc, Novartis AG, Pfizer Inc, Mylan N.V. and Bristol-Myers Squibb.

Years Covered in the Study:

Historic Year: 2017-2018

Base Year: 2019

Estimated Year: 2020

Forecast Year: 2028

Objectives of this report:

  • To estimate market size for the thyroid cancer therapeutics market on regional and global basis.
  • To identify major segments in the thyroid cancer therapeutics market and evaluate their market shares and demand.
  • To provide a competitive scenario for the thyroid cancer therapeutics market with major developments observed by key companies in the historic years.
  • To evaluate key factors governing the dynamics of the thyroid cancer therapeutics market with their potential gravity during the forecast period.

Reasons to Buy This Report:

  • Provides niche insights for decision about every possible segment helping in strategic decision making process.
  • Market size estimation of the thyroid cancer therapeutics market on a regional and global basis.
  • A unique research design for market size estimation and forecast.
  • Identification of major companies operating in the market with related developments
  • Exhaustive scope to cover all the possible segments helping every stakeholder in the thyroid cancer therapeutics

Customization:

This study is customized to meet your specific requirements:

  • By Segment
  • By Sub-segment
  • By Region/Country
  • Product Specific Competitive Analysis

For more information, contact: sales@quincemarketinsights.com